A COMPARATIVE STUDY OF EFFICACY ON GLYCEMIC CONTROL BY GLIMEPIRIDE VERSUS TENELIGLIPTIN AS AN ADD ON TO METFORMIN THERAPY IN TYPE 2 DIABETES MELLITUS PATIENTS

SASHIDHAR REDDY BOMMINENI; P. SHRAVANI; J. SHYAM; M. ALEKHYA; B. SRIKANTH

doi:10.22159/ijcpr.2022v14i2.1939

Authors

SASHIDHAR REDDY BOMMINENI RVM Institute of Medical Sciences and Charitable Trust Hospital, Laxmakkapally, Mulugu Mondal, Siddipet 502279, Telangana
P. SHRAVANI RVM Institute of Medical Sciences and Charitable Trust Hospital, Laxmakkapally, Mulugu Mondal, Siddipet 502279, Telangana
J. SHYAM RVM Institute of Medical Sciences and Charitable Trust Hospital, Laxmakkapally, Mulugu Mondal, Siddipet 502279, Telangana
M. ALEKHYA RVM Institute of Medical Sciences and Charitable Trust Hospital, Laxmakkapally, Mulugu Mondal, Siddipet 502279, Telangana
B. SRIKANTH RVM Institute of Medical Sciences and Charitable Trust Hospital, Laxmakkapally, Mulugu Mondal, Siddipet 502279, Telangana

DOI:

https://doi.org/10.22159/ijcpr.2022v14i2.1939

Keywords:

Metformin, Glimepiride, Teneligliptin, FBS, PLBS, HbA1c

Abstract

Objective: In our study, the objective was to evaluate the effectiveness of glycemic control of Glimepiride versus Teneligliptin for 2nd-line therapy in combination with Metformin in T2DM patients.

Methods: A Randomized, Observational, Prospective study has been conducted in outpatient and inpatient departments of General Medicine in RVM Hospital (Laxmakkapally, Mulugu, Siddipet, Telangana). A total of 100 patients with T2DM were recruited in our study in which 50 patients were in Group A (Metformin-Glimepiride) and the other 50 patients were in Group B (Metformin-Teneligliptin). The comparative assessment of efficacy was conducted using glycemic parameters such as FBS, PPBG and HbA1c to interpret the results.

Results: The mean difference values of HbA1c pre-treatment and post-treatment of Group A were calculated as 1.47 and of Group B was 0.83. The mean difference values FBS pre-treatment and post-treatment of Group A were found to be 56.96 and Group B was 29.62. The PLBS mean difference at Pre-treatment and Post-treatment of Group A and Group B was obtained to be 115.8 and 52.58, respectively.

Conclusion: From the results obtained, we hereby conclude that, though there was no large difference between the lowering of HbA1c values by two Groups, the FBS and PLBS levels were diminished significantly by Group A (Metformin-Glimepiride) than Group B (Metformin Teneligliptin). Therefore, Glimepiride is considered to be more beneficial than Teneligliptin when combined with Metformin Monotherapy.

Downloads

Download data is not yet available.

References

WHO diabetes. https://www.who.int/health-topics/diabetes.

International Diabetes Federation (internet source). https://diabetesatlas.org/upload/resources/material/20200106_152211_IDFATLAS9e-final-web.pdf. [Last accessed on 15 Feb 2022].

Tivoli C. Beta cells in type-1 diabetes: victims or activators of T cell response. Diabetes Metab (Paris). 2002;28:267-9.

Kumar PJ, Clark M. Textbook of clinical medicine. Pub. Philadelphia: Saunders; 2002. p. 1099-121.

Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J Endocrinol Metab. 2016;20(4):546-51. doi: 10.4103/2230-8210.183480, PMID 27366724.

Richards K. Sulfonylurea agents and combination products drug class review; 2013.

Jindal S, Gangopadhyay KK, Santhosh R, Donagaon S, Chopra V, Grijesh Paserkar, V Mohan. Efficacy of the modern SU glimepiride in reducing hyperglycemia in T2DM. J Assoc Phys India. 2019;67.

Tandon T, Dubey AK, Srivastava S, Manocha S, Arora E, Hasan N. A pharmacoeconomic analysis to compare the cost-effectiveness of metformin plus teneligliptin with metformin plus Glimepiride in patients of type-2 diabetes mellitus. J Family Med Prim Care. 2019;8(3):955-9. doi: 10.4103/jfmpc.jfmpc_22_19. PMID 31041232.

Lim PC, Chong CP. What’s next after metformin? focus on sulphonylurea: add-on or combination therapy. Pharm Pract (Granada). 2015;13(3):606. doi: 10.18549/PharmPract.2015.03.606, PMID 26445623.

Zhang Y, McCoy RG, Mason JE, Smith SA, Shah ND, Denton BT. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care. 2014;37(5):1338-45. doi: 10.2337/dc13-1901, PMID 24574345.

Lim PC, Chong CP. What’s next after metformin? focus on sulphonylurea: add-on or combination therapy. Pharm Pract (Granada). 2015;13(3):606. doi: 10.18549/ PharmPract.2015.03.606, PMID 26445623.

Zhang Y, McCoy RG, Mason JE, Smith SA, Shah ND, Denton BT. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care. 2014;37(5):1338-45. doi: 10.2337/dc13-1901, PMID 24574345.

Gitt AK, Bramlage P, Binz C, Krekler M, Deeg E, Tschope D. Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real-world setting-results of the 1-year follow-up of the prospective DiaRegis registry. Int J Clin Pract. 2013;67(10):1005-14. doi: 10.1111/ijcp.12179, PMID 23981060.

Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ. 2-year efficacy and safety of linagliptin compared with Glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-83. doi: 10.1016/S0140-6736(12)60691-6, PMID 22748821.

Devarajan TV, Venkataraman S, Kandasamy N, Oomman A, Boorugu HK, Karuppiah SKP, Balat D. Comparative evaluation of safety and efficacy of Glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: Indian multicentric randomized trial-START study. Indian J Endocrinol Metab. 2017;21(5):745-50. doi: 10.4103/ijem.IJEM_176_17, PMID 28989886.

Nishanth T, Maheshwari CU, Lakshmi RS, Sri D, Goud P, Tabassum K, Nadeem MT. A study to compare the efficacy of metformin-glimepiride versus metformin-Teneligliptin in type II diabetic patients. Int J Pharm Sci Res. 2018;9(12):5258-64. doi: 10.13040/IJPSR.0975-8232.9(12).5258-64.